^(18)F-deoxyglucose positron emission tomography/computed tomography(^(18)F-FDG PET/CT)is a functional imaging modality.It has certain advantages over other imaging modalities,such as X-ray,CT,and magnetic resonance i...^(18)F-deoxyglucose positron emission tomography/computed tomography(^(18)F-FDG PET/CT)is a functional imaging modality.It has certain advantages over other imaging modalities,such as X-ray,CT,and magnetic resonance imaging,in multiple myeloma(MM).Moreover,both the International Myeloma Working Group and the British Society of Hematology recommend PET/CT as one of the imaging modalities for MM.However,many criteria for the application of PET/CT for evaluating MM in clinical practice have not been determined.Recently,there have been many new advances in the application of PET/CT in MM.This study was designed to review the recent advances in PET/CT for assessing MM.展开更多
目的研究血清CC型趋化因子2(CC type chemotactic factor 2,CCL2)、CCL18与声门型喉癌患者临床病理参数和预后的关系。方法选择邯郸市中心医院和河北工程大学附属医院2015年8月~2018年12月收治的168例声门型喉癌患者为研究对象,受试者...目的研究血清CC型趋化因子2(CC type chemotactic factor 2,CCL2)、CCL18与声门型喉癌患者临床病理参数和预后的关系。方法选择邯郸市中心医院和河北工程大学附属医院2015年8月~2018年12月收治的168例声门型喉癌患者为研究对象,受试者工作特征(ROC)曲线确定血清CCL2、CCL18最佳截点,将患者分为CCL2高表达组和低表达组、CCL18高表达组和低表达组,分析血清CCL2、CCL18水平与声门型喉癌患者临床病理参数的关系,采用Kaplan-Meier曲线和Log-Rankχ^(2)检验分析血清CCL2高表达组和低表达组、CCL18高表达组和低表达组的5年无病生存率,采用Cox回归模型分析声门型喉癌预后的影响因素,并分析血清CCL2和CCL18表达与肿瘤复发/转移的关系。结果根据ROC曲线计算得出CCL2、CCL18的最佳截点分别为100.81、218.99 pg/ml。相较于CCL2、CCL18低表达组,CCL2、CCL18高表达组T3~T4a级、N1~N3级、肿瘤低分化占比明显升高(P<0.05)。168例声门型喉癌患者随访5年失访8例,完成随访160例。67例发生复发/转移,39例因复发/转移而死亡,肿瘤复发/转移率为41.88%(67/160),无病生存率为58.13%(93/160)。Kaplan-Meier生存曲分析显示,血清CCL2、CCL18高表达组5年无病生存率均明显低于血清CCL2、CCL18低表达组(P<0.05)。Cox回归分析显示,T分级升高、颈淋巴结复发、N分级升高、咽喉部复发、CCL2高表达、CCL18高表达是声门型喉癌预后不良的危险因素(P<0.05)。分析血清CCL2和CCL18表达与肿瘤复发/转移的关系发现,CCL2和CCL18均高表达时其复发/转移率明显高于CCL2和CCL18均低表达、CCL2低表达且CCL18高表达、CCL2高表达且CCL18低表达,差异比较有统计学意义(χ^(2)=10.450,P=0.015)。结论声门型喉癌患者血清CCL2、CCL18高表达与T分级、N分级、肿瘤低分化和预后不良显著相关。展开更多
文摘^(18)F-deoxyglucose positron emission tomography/computed tomography(^(18)F-FDG PET/CT)is a functional imaging modality.It has certain advantages over other imaging modalities,such as X-ray,CT,and magnetic resonance imaging,in multiple myeloma(MM).Moreover,both the International Myeloma Working Group and the British Society of Hematology recommend PET/CT as one of the imaging modalities for MM.However,many criteria for the application of PET/CT for evaluating MM in clinical practice have not been determined.Recently,there have been many new advances in the application of PET/CT in MM.This study was designed to review the recent advances in PET/CT for assessing MM.